| 3.8 0.55 (16.92%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.84 |
1-year : | 5.66 |
| Resists | First : | 4.15 |
Second : | 4.84 |
| Pivot price | 3.6  |
|||
| Supports | First : | 3.47 |
Second : | 3.04 |
| MAs | MA(5) : | 3.4 |
MA(20) : | 3.61 |
| MA(100) : | 3.09 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 40 |
D(3) : | 24.8 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 24.42 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XFOR ] has closed below upper band by 26.6%. Bollinger Bands are 31.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.82 - 3.83 | 3.83 - 3.85 |
| Low: | 3.22 - 3.23 | 3.23 - 3.25 |
| Close: | 3.77 - 3.8 | 3.8 - 3.83 |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Mon, 01 Dec 2025
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha
Sun, 30 Nov 2025
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research - MarketBeat
Wed, 05 Nov 2025
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Mon, 27 Oct 2025
X4 Pharma (NASDAQ: XFOR) closes $155.3M offering; underwriters' option fully exercised - Stock Titan
Fri, 24 Oct 2025
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering - GlobeNewswire
Wed, 22 Oct 2025
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 8.129e+007 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 1,790 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.037e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -279.9 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 280.9 % |
| Return on Equity (ttm) | -33.6 % |
| Qtrly Rev. Growth | 3.398e+007 % |
| Gross Profit (p.s.) | 512.38 |
| Sales Per Share | -373.5 |
| EBITDA (p.s.) | 6.73333e+007 |
| Qtrly Earnings Growth | -9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -103 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.65 |
| Dividend | 0 |
| Forward Dividend | 1.94e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|